Stephen Squinto, recruited by JP Morgan a few years ago to head up its Life Sciences Private Capital team, is raising a ...

Pfiz­er is dou­bling down on its com­mit­ment to Chi­na as the com­pa­ny con­tin­ues to face ac­tivist pres­sure around its ...

The head of As­traZeneca’s op­er­a­tions in Chi­na has been de­tained by au­thor­i­ties there, the com­pa­ny con­firmed.

Coming out of Covid, the vaccine market appeared to experience a renaissance as the innovations of the pandemic unleashed new ...

Gilead said its Covid-19 antiviral Veklury had $692 million in third-quarter sales, far more than the $270 million Wall ...

Genmab is culling a trio of early oncology assets to focus on upcoming milestones for its late-stage programs that include an ...

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Coherus is resuming the supply of its ...

Aurinia Pharmaceuticals is reducing 45% of its workforce and is bringing in a new board member as part of a broader restructuring. The company ...

Plus, news about ADC Therapeutics, Celldex and Viracta Therapeutics: Geron inks up to $375M royalty and debt deal: The company now has a $125 million deal ...

Denali revealed new topline data Wednesday for an early-stage program that's a part of the FDA’s Operation Warp Speed for rare diseases. The program, DNL126, is an ...

Moderna revealed the consequences of its late start in the market for RSV vaccines, reporting just $10 million in third-quarter sales from the new shot. Those numbers are a fraction ...

Sarepta Therapeutics is stopping development of vesleteplirsen, an experimental exon 51-skipping therapy for Duchenne muscular dystrophy patients with certain mutations. It's also halting work on all ...